Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates
multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or …

BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell
maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We …

These guidelines are a consensus work of a considerable number of members of the
immunology and flow cytometry community. They provide the theory and key practical …

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-
cell therapy in multiple myeloma (MM). Despite promising objective response rates, most …

Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …